EGFR and non-small cell lung carcinoma: Although the recent CHRYSALIS-2 study (cohort C) demonstrated promising efficacy for amivantamab plus lazertinib in patients with NSCLC harboring uncommon EGFR mutations [11] research into single-agent TKI regimens is still warranted because of the high toxicity associated with the amivantamab plus lazertinib combination.